The scale of the problem makes the details of the survey worth unpacking. Insulin remains the cornerstone of diabetes management when lifestyle modification and oral agents fail to achieve glycaemic targets. Physiologically, the hormone performs two essential tasks: it drives glucose uptake into peripheral tissues such as muscle and fat, and it suppresses the liver’s production of glucose. When these actions are insufficient, chronic hyperglycaemia insidiously damages blood vessels and nerves, setting the stage for cardiovascular disease, nephropathy, retinopathy, neuropathy and premature death. Yet despite well-defined guidelines and decades of evidence, clinicians worldwide delay insulin initiation, a phenomenon researchers call therapeutic inertia. In Lahore, that inertia has now been measured with statistical precision, and the results suggest it is driven by a dense web of patient, physician and health-system factors that reinforce one another.

The research team, led from The University of Lahore, recruited physicians from Internal Medicine, Endocrinology, Gastroenterology and Nephrology at a public sector tertiary hospital. Using a calculated minimum sample of 384, they invited 910 eligible doctors and achieved a remarkable 88.8 percent response rate, with 808 completed questionnaires. The instrument, refined through a pilot study of 20 physicians and content-validated by a panel of 10 endocrinologists, achieved a content validity index of 0.90 and acceptable internal consistency, with Cronbach’s alpha values of 0.73 for the barriers section and 0.79 for the feedback section. Respondents were demographically diverse: 54.3 percent were women, 58.5 percent were aged 41 to 55, and the largest qualification group held the FCPS fellowship, followed by MBBS, MRCP and MRCS credentials. Most participants managed panels in which 11 to 30 percent of patients required insulin.

The barrier data, collected on four-point Likert scales and dichotomised for analysis, paint a picture of systemic strain. Beyond the twin giants of poor education and hypoglycaemia fear, physicians reported complex administration techniques as a barrier in 84.1 percent of cases, inadequate communication in 84 percent, fear of needles in 83 percent, misconceptions about weight gain in 81.5 percent and financial constraints in 81.4 percent. Patient resistance to insulin itself was ubiquitous. These figures resonate strikingly with international comparisons cited by the authors: in Trinidad, primary care physicians flagged needle fear in 98.6 percent of cases; in Saudi Arabia’s Jazan region, 80.5 percent reported injection phobia among patients; and in Nigeria, fear of hypoglycaemia topped the list at 81.3 percent. The consistency across such different health systems suggests that the psychology of insulin refusal is close to universal, even if its intensity varies with local literacy and economic conditions.

Statistical testing revealed that the experience of barriers was not evenly distributed across the medical workforce. Kruskal-Wallis tests with Bonferroni adjustment found highly significant differences by qualification in several domains. Patients’ resistance to insulin, difficulty explaining the differences between short-acting and long-acting formulations, the influence of cultural beliefs, and hesitation rooted in hypoglycaemia fear and regimen complexity all varied significantly across degree holders, with p values below 0.001. Binary logistic regression added a demographic dimension: male physicians were significantly more likely than female colleagues to report barriers, with an adjusted odds ratio of 1.392. Holders of the MRCP qualification faced elevated odds of 1.657 after adjustment, while physicians with 5 to 10 years of clinical experience were markedly less likely to report barriers than those with fewer than 5 years, with an adjusted odds ratio of 0.588. The authors caution that the reasons underlying the gender difference remain unclear and may reflect differences in clinical experience or practice patterns rather than any intrinsic factor.

The experience gradient deserves particular attention. That mid-career physicians encounter fewer obstacles than their juniors suggests a learnable skill set: the counselling techniques, cultural fluency and regimen-management strategies that accumulate with practice. Conversely, the finding that MRCP holders reported more barriers may reflect the complexity of the patients they manage or differing thresholds for perceiving problems. Either way, the authors argue, the pattern points toward targeted professional development rather than one-size-fits-all training. In a country where literacy rates lag behind those of many comparison nations, the dominance of patient education as the leading barrier, reported by 85.8 percent of respondents, takes on added weight. A parallel study from Singapore found that educational level was significantly associated with patients’ willingness to accept insulin, and the Lahore data are consistent with that relationship operating at population scale.

Perhaps the most actionable portion of the study is the physicians’ own prescription for reform. When asked what support was lacking in helping patients understand insulin therapy, the most common answer, endorsed with highly significant differences across qualification groups, was access to diabetes educators. For improving adherence, regular follow-up appointments dominated, and for sustaining patient responses over time, regular follow-up and support was the leading recommendation, chosen by 156 FCPS holders and 105 MRCP holders. On communication, an overwhelming majority across all credential groups selected a combined approach: written instructions, verbal counselling and shared decision-making. When asked how to improve the prescribing process itself, most favoured an all-of-the-above package of streamlined electronic prescribing systems, better patient education resources, improved access to formulary information and closer collaboration with diabetes specialists.

These recommendations align with a growing evidence base. A 2025 systematic review by Aslam and colleagues found that behavioural intervention programmes incorporating patient education, counselling and structured follow-up are effective in preventing and managing diabetes in adults. Pakistan’s rapidly expanding telecommunications infrastructure offers a plausible delivery channel for such programmes, potentially extending education and follow-up beyond hospital walls. Meanwhile, screening initiatives such as the Risk Assessment of Pakistani Individuals for Diabetes aim to identify high-risk individuals before complications develop. The survey’s authors also situate their findings within the broader literature on therapeutic inertia, which attributes roughly 20 percent of clinical delay to health-system factors, including medication cost, resource limits, discontinuity of care and workforce overload, and about 30 percent to patient-related factors such as injection phobia, fear of weight gain and low health literacy.

The study is not without limitations, and the authors are candid about them. Convenience sampling at a single urban tertiary hospital limits generalizability, particularly to rural settings where the majority of Pakistan’s population receives care. Self-reported data carry the risk of recall and social desirability bias. The inclusion of an all-of-the-above response category may have introduced overlap in the chi-square analyses, and the regression models did not formally assess multicollinearity or clustering by department. Crucially, because only physicians were surveyed, the barriers documented are physician perceptions, which may not fully mirror patients’ lived experience. The cross-sectional design identifies associations but cannot establish causation, and the interventions physicians recommended were not tested within the study itself.

Even with those caveats, the research delivers a clear message at a moment when Pakistan’s diabetes epidemic is accelerating. Insulin works; the obstacle is everything surrounding it. The Lahore survey transforms anecdote into quantified evidence, showing that the path to better glycaemic control runs through diabetes educator access, structured follow-up, culturally attuned communication and financial support, tailored to the experience level and professional background of the prescriber. Future intervention-based studies, the authors conclude, must now test whether these physician-endorsed strategies actually reduce barriers and improve outcomes. For a country where one in four urban adults lives with diabetes, the cost of therapeutic inertia is measured not in percentages but in amputations, blindness and lost years of life. What 808 physicians have described is, in effect, a map of where the system is failing, and a first draft of how to fix it.

Subject of Research: Barriers to insulin prescribing and physician-recommended interventions in diabetes care in Lahore, Pakistan

Article Title: Insulin Prescribing Challenges and Physician‐Suggested Interventions: Evidence From a Tertiary Care Hospital in Lahore, Pakistan

Article References: Aamir, M., Nafeesa, B., Aslam, A., Ghulam Mustafa, A., Elahi, M., Elahi, A., Barkat, K., Ashraf, M. U., Wahab, M. S. A., & Akhtar, S. S. (2026). Insulin Prescribing Challenges and Physician‐Suggested Interventions: Evidence From a Tertiary Care Hospital in Lahore, Pakistan. Endocrinology, Diabetes & Metabolism, 9(5), Article e70337. https://doi.org/10.1002/edm2.70337

Image Credits: AI Generated

DOI: 10.1002/edm2.70337

Keywords: insulin therapy, type 2 diabetes, Pakistan, therapeutic inertia, patient education, hypoglycaemia, physician survey, diabetes educators, cross-sectional study, tertiary care, medication adherence, health systems

The study used the Pittsburgh Sleep Quality Index, or PSQI, a validated instrument that scores sleep across seven components including duration, latency, disturbances, efficiency, and daytime dysfunction. Participants recorded a median PSQI score of 7, with an interquartile range stretching from 6 to 20, a distribution indicating that while many patients hovered near the threshold of disturbed sleep, a substantial minority experienced severe and multifaceted sleep problems. A global score above 5 conventionally signals poor sleep quality, and the 150 participants who crossed that line represent a burden that clinicians in the municipality had not previously quantified.

What elevates the study beyond a simple prevalence count is its parallel measurement of psychological and social variables. Each participant also completed the Perceived Stress Scale, a ten-item questionnaire capturing how unpredictable, uncontrollable, and overloaded respondents find their lives, and the Multidimensional Scale of Perceived Social Support, which assesses support from family, friends, and significant others. The statistical relationships that emerged were striking. Perceived stress correlated positively with PSQI scores with a Spearman coefficient of 0.668, while social support correlated inversely at minus 0.645, both highly significant. In epidemiological terms, these are strong associations, suggesting that the emotional and social context of living with a chronic disease may matter as much as the disease itself when it comes to sleep.

To test whether these correlations held up under scrutiny, the researchers turned to multivariable logistic regression, a technique that estimates the independent effect of each factor while adjusting for all the others. The results were consistent with the correlation analysis. Every five-point increase in perceived stress nearly quadrupled the odds of poor sleep quality, with an adjusted odds ratio of 3.67 and a 95 percent confidence interval of 1.99 to 6.75. Conversely, every five-point increase in perceived social support cut the odds by nearly half, with an adjusted odds ratio of 0.57 and a confidence interval of 0.41 to 0.79. In plain terms, stressed patients slept poorly, and supported patients slept better, regardless of their other characteristics.

Age and treatment regimen also left clear fingerprints on sleep outcomes. Compared with adults aged 30 to 44, participants aged 45 to 60 and those older than 60 faced significantly higher odds of poor sleep, a pattern consistent with the known age-related erosion of sleep architecture, in which deep slow-wave sleep diminishes and nocturnal awakenings become more frequent. Treatment type mattered as well: patients using insulin, or combining insulin with oral agents, were more likely to be poor sleepers than those on oral medication alone. The authors suggest several plausible mechanisms, including nocturnal hypoglycemia, the burden of injection routines, and the fact that insulin prescription typically marks longer disease duration and greater metabolic complexity.

One finding stands out for its sheer magnitude. Participants reporting high levels of physical activity had dramatically lower odds of poor sleep quality, with an adjusted odds ratio of 0.11 and a confidence interval of 0.02 to 0.55. Although the wide interval reflects a small number of highly active participants and warrants caution, an odds reduction of nearly 90 percent is difficult to ignore. The result aligns with a substantial international literature linking regular exercise to improved sleep onset, sleep continuity, and sleep depth, and it hints at a practical, low-cost intervention available even in resource-constrained primary care settings.

The biological plausibility of the stress-sleep connection in diabetes is well established. Chronic hyperglycemia triggers osmotic diuresis, causing nocturia that fragments sleep, while sleep deprivation in turn impairs insulin sensitivity and glucose tolerance, creating a feedback loop in which poor sleep worsens glycemic control and poor glycemic control worsens sleep. Add the psychological load of managing a lifelong condition, often with financial strain and limited family resources, and the high prevalence of disturbed sleep in this population becomes less surprising. The strong inverse association with social support suggests that this loop may be buffered by the people around the patient, a modifiable factor that few diabetes programs currently measure.

The study’s setting gives its findings particular weight. Evidence on sleep and diabetes from sub-Saharan African primary care has been sparse, and most of what is known comes from high-income countries with different health systems, diets, and social structures. By recruiting across the Mampong Municipal Government Hospital and the Kofiase and Adudwan health centres, the researchers captured a multicentre sample that reflects routine care rather than specialist clinics. The cross-sectional design, however, imposes real limits: because stress, support, and sleep were measured at the same moment, the data cannot establish which factor drives which. It is entirely possible that poor sleep amplifies perceived stress just as stress disrupts sleep, and only longitudinal or interventional studies can untangle the direction of causation.

Even so, the practical implications are immediate. The authors argue that sleep quality and psychosocial assessment should be woven into routine diabetes care, a recommendation that requires no new drugs or expensive equipment. A short PSQI administered at clinic visits could flag the more than one-third of patients whose sleep is quietly undermining their metabolic health, while screening for high perceived stress and low social support could identify those most at risk. Given that sleep disturbance is associated with worse glycemic control, greater diabetes distress, and reduced quality of life, treating sleep as a vital sign in diabetes management is an idea whose time may have come, in Mampong and well beyond it.

The study, which received no external funding and was approved by the Ghana Health Service Ethics Review Committee, adds Ghana to the growing map of countries documenting the hidden burden of sleep disorders among people with chronic disease. As diabetes prevalence continues to climb across Africa, the message from Mampong is clear: the fight against type 2 diabetes is not only fought with medication and diet, but also, increasingly, in the quality of patients’ sleep and the strength of the social ties that surround them.

Subject of Research: Sleep quality and its psychosocial and clinical determinants among adults with type 2 diabetes in Ghana

Article Title: Sleep quality and associated factors among adults living with type 2 diabetes mellitus in Mampong municipality, Ghana: a multicentre cross-sectional study

Article References: Sleep quality and associated factors among adults living with type 2 diabetes mellitus in Mampong municipality, Ghana: a multicentre cross-sectional study. (n.d.). https://doi.org/10.1186/s12902-026-02585-4

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02585-4

Keywords: type 2 diabetes, sleep quality, Pittsburgh Sleep Quality Index, perceived stress, social support, physical activity, Ghana, insulin therapy, cross-sectional study, glycemic control, primary care, BMC Endocrine Disorders

The study is notable less for its size than for its novelty. Until now, all evidence on this topic came from questionnaires and interviews rather than measured physiology. In one frequently cited survey of 53 young adults with type 1 diabetes, roughly one third reported fearing hypoglycaemia during sexual activity. But no one had ever tracked what actually happens to blood glucose in the hours surrounding sex. The Warsaw team set out to close that gap by combining real-time CGM data with participant-reported events, creating the first objective physiological picture of glucose dynamics during and after sexual intercourse in people with type 1 diabetes.

Dr Orłowska explained the clinical reasoning behind the research. On paper, sex is physical exertion like any other, and exertion lowers glucose. In practice, however, it behaves differently from planned exercise. A person preparing for a workout can reduce an insulin dose, eat carbohydrates beforehand, or activate an exercise mode on an insulin pump. Sexual activity, by contrast, is usually spontaneous, and it typically occurs in the evening or at night — precisely the window in which severe and unnoticed hypoglycaemia is most likely. Compounding the problem, she noted, is silence: patients routinely discuss exercise with their diabetologists and receive concrete advice, but almost nobody asks about sex, so the fear is never addressed. Yet sexual life is central to quality of life, and fear of hypoglycaemia can lead people to avoid intimacy entirely.

To investigate, the researchers enrolled 12 adults with type 1 diabetes — seven women and five men — in a prospective observational study. Participants had a median age of 36 years, ranging from 21 to 64, and a mean body mass index of 24 kg/m². All wore CGM devices, either the FreeStyle Libre 2 or the Guardian 4. Six were treated with multiple daily insulin injections and six with insulin pump therapy, including two using automated insulin delivery systems. None of the five male participants reported erectile dysfunction. Over a three-month period, participants marked each instance of sexual intercourse in their CGM application, allowing the researchers to analyse glucose data from two hours before to six hours after every event.

In total, 110 sexual intercourse events were recorded. A telling behavioural detail emerged: all participants using insulin pump therapy reported removing their devices during sex, meaning glucose readings during the events themselves came from the surrounding CGM trace rather than pump-integrated data. Despite the potential for exertion-related glucose drops, no clinically significant hypoglycaemia was observed anywhere in the dataset. Blood sugar changes were also unrelated to insulin therapy mode or to how long a participant had lived with diabetes, suggesting the response pattern is broadly consistent across treatment approaches.

The most striking finding was the bidirectionality of the glucose response. In 64 events, representing 58 percent of the total, mean post-intercourse glucose fell by 27 percent, from 180 to 132 mg/dL — a statistically significant decrease. In the remaining 46 events, or 42 percent, glucose rose by 34 percent, from 122 to 164 mg/dL, also statistically significant. Both increasing and decreasing patterns were observed within every single participant, meaning no individual could be classified as a consistent

The direction of the glucose response was not random. Higher glucose levels before intercourse were associated with a greater subsequent fall when glucose declined, and with a smaller rise when glucose increased, suggesting the body’s response may partly depend on the starting metabolic state. This bidirectional pattern echoes what is known about exercise physiology more broadly: physical activity typically lowers glucose by increasing muscle glucose uptake, but factors such as adrenaline, anticipatory stress, and circulating insulin levels can push glucose in the opposite direction. Sexual activity combines elements of exertion with emotional arousal, and the new data suggest these competing forces can net out in either direction in any given encounter.

Timing emerged as a meaningful variable. Of the 110 recorded events, 66 occurred at night, defined as between 20:00 and 06:00, and these nighttime events were associated with a statistically significant reduction in glucose levels, from a mean of 165 to 147 mg/dL. Daytime events, numbering 44, produced essentially no change, with mean glucose moving only from 144 to 143 mg/dL. The researchers also found no difference between mean glucose measured two hours after intercourse and six hours after, indicating that any glucose effects of sexual activity had largely settled within the first two hours rather than producing delayed drops hours later. That detail matters clinically, since delayed-onset hypoglycaemia is a well-recognised hazard after vigorous exercise and a common source of anxiety among people using insulin.

Body composition appeared to influence the response as well. Participants with a body mass index of 25 or higher showed a statistically significant post-intercourse glucose decrease of 10.7 percent, from 150 to 134 mg/dL, while those with a BMI under 25 showed a smaller, non-significant decline of 5.6 percent, from 159 to 150 mg/dL. The authors suggest this may reflect differences in energy expenditure, insulin sensitivity, or muscle mass, though the small sample size makes it impossible to draw firm conclusions. Diabetes duration, meanwhile, had no detectable effect on glucose responses, and neither did the mode of insulin delivery, whether multiple daily injections, conventional pump therapy, or automated insulin delivery.

The study’s limitations deserve emphasis. Twelve participants and 110 events are enough to generate hypotheses and provide reassurance, but not enough to establish definitive risk estimates for subgroups. All participants were adults in mid-life on average, with a normal mean BMI, and none of the men reported erectile dysfunction, so the findings may not extend to people with diabetes-related sexual dysfunction, older adults, or those with hypoglycaemia unawareness, a condition in which the normal warning symptoms of falling glucose are blunted. People with impaired awareness of hypoglycaemia are generally considered at higher risk during any unplanned activity, and clinicians may reasonably advise more cautious monitoring for them regardless of these results.

There is also the question of what the CGM trace can and cannot capture. Because every pump user removed their device during intercourse, the analysis relied on interstitial glucose readings from the surrounding period, and interstitial glucose lags behind blood glucose by several minutes to more than a quarter of an hour. Rapid changes during the event itself could therefore be somewhat smoothed or delayed in the recorded data. The researchers defined clinically significant hypoglycaemia according to standard thresholds used in diabetes research, and no readings crossed those thresholds, but the study was not powered to detect rare events. A single severe episode among hundreds of encounters would not necessarily appear in a dataset of this size.

Even with those caveats, the findings carry practical weight for clinical counselling. Diabetes care guidelines encourage clinicians to discuss the impact of physical activity on glucose, but sexual activity is rarely mentioned, and patients rarely raise it themselves. Dr Orłowska and her colleagues argue that the silence itself is harmful: fear of hypoglycaemia during sex can lead to avoidance of intimacy, strain on relationships, and reduced quality of life, all of which are recognised concerns in diabetes care yet seldom addressed in routine consultations. Objective evidence that intercourse does not typically provoke dangerous glucose lows gives clinicians a concrete, evidence-based starting point for those conversations.

The results also offer a framework for individualised advice rather than blanket reassurance. Because starting glucose level, time of day, and BMI all appeared to shape the glucose response, people with type 1 diabetes and their clinicians can use these factors when thinking about personal risk. Someone beginning sexual activity with a glucose level already trending low at night may reasonably choose to check a reading beforehand or keep fast-acting carbohydrates within reach, while someone starting from a higher glucose level may see little change or even a rise. The observation that glucose effects settled within two hours, with no delayed divergence at the six-hour mark, may further ease worries about overnight lows following evening intimacy.

The authors close with a reminder about technology access. In an ideal world, they note, every person with type 1 diabetes would use continuous glucose monitoring; those who do not may have no way of knowing whether they experience hypoglycaemia during sex or in any other setting. For the growing number of CGM users, however, the device itself offers a simple tool: marking events and reviewing the surrounding trace can turn an abstract fear into personal data. As the first study to measure glucose objectively in this context, the Warsaw work transforms a question that has lived only in surveys and unspoken anxieties into an answerable physiological one, and it opens the door to larger studies in more diverse populations.

Subject of Research: Glucose responses to sexual intercourse in adults with type 1 diabetes measured by continuous glucose monitoring

Article Title: Sex is safe in type 1 diabetes, shows small study using continuous glucose monitoring devices

Article References: Sex is safe in type 1 diabetes, shows small study using continuous glucose monitoring devices. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 1 diabetes, continuous glucose monitoring, hypoglycaemia, sexual intercourse, EASD, blood glucose, insulin therapy, quality of life, observational study, Medical University of Warsaw, nocturnal hypoglycaemia, diabetes counselling